Coronary Revascularization in Diabetic Patients [FREEDOM TRIAL]

ID Number 02-0163

Principal Investigator(s)
Valentin Fuster

Department(s) or Division(s)


FREEDOM (Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease) is a multicenter, two-arm, open label, prospective, randomized superiority trial with equal allocation, of 5 years duration with a minimum of 3 years of follow-up. The main objective of the study is to evaluate whether PCI with drug-eluting stenting (PCI/DES) is more or less effective than the existing standard of care, CABG. Identifier: NCT00086450

Contact Information
Michael E. Farkouh, MD
(212) 659-9181

Recruiting Patients: No